CY1121237T1 - Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w - Google Patents

Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w

Info

Publication number
CY1121237T1
CY1121237T1 CY20191100169T CY191100169T CY1121237T1 CY 1121237 T1 CY1121237 T1 CY 1121237T1 CY 20191100169 T CY20191100169 T CY 20191100169T CY 191100169 T CY191100169 T CY 191100169T CY 1121237 T1 CY1121237 T1 CY 1121237T1
Authority
CY
Cyprus
Prior art keywords
herv
expression
reinmyelination
associations
exclusion
Prior art date
Application number
CY20191100169T
Other languages
English (en)
Inventor
Hervé Perron
Reza FIROUZI
Patrick KÜRY
Raphaël FAUCARD
Alexandra MADEIRA
Julie Joanou
Original Assignee
Geneuro Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro Sa filed Critical Geneuro Sa
Publication of CY1121237T1 publication Critical patent/CY1121237T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Η παρούσα εφεύρεση ασχολείται με καινοτόμες ενώσεις και συνθέσεις για πρόληψη και/ή αγωγή ενός νεο-ανακαλυφθέντος επιβλαβούς μηχανισμού, ο οποίος αποκλείει την ικανότητα επιδιόρθωσης ενδογενούς μυελίνης του νευρικού συστήματος (NS) ενηλίκων σε παθήσεις που συσχετίζονται με την έκφρασης της πρωτεΐνης φακέλου (ENV) HERV-W, ειδικότερα του υπο-τύπου MSRV αυτής.
CY20191100169T 2012-10-02 2019-02-07 Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w CY1121237T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261708779P 2012-10-02 2012-10-02
US201261746792P 2012-12-28 2012-12-28
PCT/EP2013/070452 WO2014053489A1 (en) 2012-10-02 2013-10-01 Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein

Publications (1)

Publication Number Publication Date
CY1121237T1 true CY1121237T1 (el) 2020-05-29

Family

ID=49274655

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100169T CY1121237T1 (el) 2012-10-02 2019-02-07 Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w
CY20211100400T CY1124378T1 (el) 2012-10-02 2021-05-11 Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100400T CY1124378T1 (el) 2012-10-02 2021-05-11 Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w

Country Status (31)

Country Link
US (2) US9840550B2 (el)
EP (2) EP2904009B1 (el)
JP (2) JP6379331B2 (el)
KR (1) KR102098033B1 (el)
CN (2) CN105709224B (el)
AU (2) AU2013326552B2 (el)
BR (1) BR112015007150A8 (el)
CA (1) CA2882781C (el)
CY (2) CY1121237T1 (el)
DK (2) DK3447070T3 (el)
EA (2) EA037253B1 (el)
EC (1) ECSP15014925A (el)
ES (2) ES2878248T3 (el)
HK (1) HK1221399A1 (el)
HR (2) HRP20190274T1 (el)
HU (2) HUE043419T2 (el)
IL (3) IL237474A0 (el)
IN (1) IN2015DN02397A (el)
LT (2) LT2904009T (el)
MX (2) MX366846B (el)
MY (1) MY172209A (el)
PL (2) PL2904009T3 (el)
PT (2) PT2904009T (el)
RS (2) RS58320B1 (el)
RU (1) RU2636355C2 (el)
SA (1) SA515360207B1 (el)
SG (1) SG11201501274VA (el)
SI (2) SI3447070T1 (el)
UA (1) UA119032C2 (el)
WO (1) WO2014053489A1 (el)
ZA (1) ZA201501491B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2949342A1 (en) * 2014-05-28 2015-12-02 Geneuro SA Antiretroviral drug targeting human endogenous retrovirus
EP3351265A1 (en) * 2017-01-20 2018-07-25 Geneuro SA Anti-herv-k envelope antibody and uses thereof
JP7122002B2 (ja) 2017-03-01 2022-08-19 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
JP7317377B2 (ja) * 2018-09-01 2023-07-31 国立大学法人北海道大学 ストレス負荷が関与する疾患を予防及び／又は治療するための医薬
US20220332799A1 (en) * 2019-09-04 2022-10-20 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
AU5829201A (en) * 2000-03-21 2001-10-03 Ms Research A/S An infective endogenous retrovirus and its association with demyelinating diseases and other diseases
WO2002056910A1 (en) 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
US20090233888A1 (en) * 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
EP2139467B1 (en) * 2007-02-08 2016-09-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
WO2009062926A1 (en) * 2007-11-12 2009-05-22 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
PT3211005T (pt) 2008-07-08 2021-06-15 Geneuro Sa Utilização terapêutica de ligandos específicos nas doenças associadas a msrv
JP2012505257A (ja) * 2008-10-13 2012-03-01 バイオヴィスタ，インコーポレイテッド 多発性硬化症治療のための組成物および方法
WO2010148323A2 (en) * 2009-06-18 2010-12-23 Whittemore Peterson Institute For Neuro-Immune Disease Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
ME02317B (me) * 2010-02-12 2016-06-20 Biogen Ma Inc Neuroprotekcija kod demijelinizacijskih bolesti

Also Published As

Publication number Publication date
LT2904009T (lt) 2019-03-12
EP3447070B9 (en) 2021-08-11
EA201590678A1 (ru) 2015-07-30
MX2019008916A (es) 2019-11-11
IL274047B (en) 2020-11-30
HUE043419T2 (hu) 2019-08-28
ZA201501491B (en) 2016-01-27
DK3447070T3 (da) 2021-05-10
CA2882781A1 (en) 2014-04-10
DK2904009T3 (en) 2019-03-11
US10752675B2 (en) 2020-08-25
KR20150064147A (ko) 2015-06-10
HUE054051T2 (hu) 2021-08-30
US9840550B2 (en) 2017-12-12
US20180066040A1 (en) 2018-03-08
JP6379331B2 (ja) 2018-08-29
EP3447070A1 (en) 2019-02-27
RU2015116149A (ru) 2016-11-27
IL274047A (en) 2020-06-30
PT3447070T (pt) 2021-05-19
MY172209A (en) 2019-11-15
CN105709224A (zh) 2016-06-29
JP2016500651A (ja) 2016-01-14
EA201791525A2 (ru) 2018-07-31
PT2904009T (pt) 2019-02-19
SA515360207B1 (ar) 2018-09-18
PL3447070T3 (pl) 2021-09-06
AU2013326552A1 (en) 2015-03-05
CN104684927A (zh) 2015-06-03
PL2904009T3 (pl) 2019-06-28
CN105709224B (zh) 2020-06-05
WO2014053489A1 (en) 2014-04-10
RS58320B1 (sr) 2019-03-29
CN104684927B (zh) 2018-06-19
IL264382B (en) 2020-05-31
RU2636355C2 (ru) 2017-11-22
HRP20210779T1 (hr) 2021-09-17
EP3447070B1 (en) 2021-02-24
AU2013326552B2 (en) 2018-05-24
ES2878248T3 (es) 2021-11-18
CA2882781C (en) 2021-06-15
EA037253B1 (ru) 2021-02-26
EP2904009A1 (en) 2015-08-12
IL264382A (en) 2019-02-28
RS61794B1 (sr) 2021-06-30
SG11201501274VA (en) 2015-05-28
HK1221399A1 (zh) 2017-06-02
EA028245B1 (ru) 2017-10-31
IL237474A0 (en) 2015-04-30
UA119032C2 (uk) 2019-04-25
JP6538138B2 (ja) 2019-07-03
HRP20190274T1 (hr) 2019-04-05
ECSP15014925A (es) 2017-07-31
EP2904009B1 (en) 2018-11-21
ES2710748T3 (es) 2019-04-26
LT3447070T (lt) 2021-06-10
AU2018217328B2 (en) 2019-09-19
SI2904009T1 (sl) 2019-04-30
IN2015DN02397A (el) 2015-09-04
BR112015007150A8 (pt) 2018-02-06
MX2015003572A (es) 2015-08-20
MX366846B (es) 2019-07-26
AU2018217328A1 (en) 2018-09-06
JP2018065814A (ja) 2018-04-26
KR102098033B1 (ko) 2020-04-08
SI3447070T1 (sl) 2021-08-31
EA201791525A3 (ru) 2018-12-28
BR112015007150A2 (pt) 2017-07-04
CY1124378T1 (el) 2022-07-22
US20150218256A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
CY1123397T1 (el) Συνθεσεις που περιλαμβανουν συνδυασμο ιπιλιμουμαμπης και νιβολουμαμπης
CY1122631T1 (el) Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1121120T1 (el) Αρυλ- ή ετεροαρυλ-υποκατεστημενες ενωσεις βενζολιου
CY1121237T1 (el) Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CY1125440T1 (el) Αντι-τιμ-3 αντισωματα και συνθεσεις
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1118744T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1120662T1 (el) Παραγωγα πυρρολαμιδιου υποκατεστημενου γλυοξαμιδιου και η χρηση αυτων ως φαρμακων για τη θεραπευτικη αντιμετωπιση της ηπατιτιδας β
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c